Principal Investigator:
Stuart Knechtle, MD, Duke University Hospital
The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Learn more:
Principal Investigator:
Flavio G. Vincenti, MD, University of California, San Francisco Medical Center
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Learn more:
